Combined Effects of Benidipine and Diltiazem in a Rat Model of Experimental Angina

Kozo Yao1,* and Shiro Shirakura1

1Biomedical Research Laboratories, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731, Japan

Received November 19, 2003; Accepted April 26, 2004

Abstract. We examined the combined effects of the calcium channel blockers 1,4-dihydropyridine (benidipine) and benzothiazepine (diltiazem) on vasopressin-induced myocardial ischemia in anesthetized rats, an experimental model of angina. Benidipine (3, 10 μg/kg, i.v.) and diltiazem (300, 1000 μg/kg, i.v.) caused dose-related inhibition of vasopressin-induced S-wave depression, an index of myocardial ischemia. Co-administration of low doses of benidipine (3 μg/kg) and diltiazem (300 μg/kg) almost completely inhibited the S-wave depression, where the efficacy was similar to that obtained with the use of high doses of benidipine (10 μg/kg) or diltiazem (1000 μg/kg). These results suggest that the administration strategy employed may be useful in the treatment of angina pectoris.

Keywords: diltiazem, benidipine, angina

Several lines of evidence have indicated that calcium channel blockers are effective in the treatment of angina pectoris. Benidipine is a 1,4-dihydropyridine calcium channel blocker possessing slow-onset and long-lasting vasodilating effects and is clinically useful in the treatment of hypertension and angina pectoris (1). Karasawa et al. (2) have reported that benidipine has beneficial effects on various experimental angina models, including an arginine vasopressin (AVP)-induced angina model.

In the treatment of angina pectoris, monotherapy using antianginal drugs is generally not completely effective for all types of angina pectoris (3). Combination therapy employing different types of agents has been used in an effort to improve on the clinical benefits of monotherapy. In fact, some clinical studies have demonstrated that the combined use of nifedipine and diltiazem was favorable in patients with angina pectoris (4–6). In an effort to evaluate the effectiveness of combination therapy, the present study employed the use of two different types of calcium channel blockers, benidipine and diltiazem. Antianginal effects pertaining to AVP-induced angina were evaluated and compared to the therapeutic efficacy obtained with the use of either drug alone.

Male Donryu rats (9–11-week-old; Japan SLC, Shizuoka) were used in this study. Rats were kept at 23 ± 1°C under a 12-h light-dark cycle, where they had free access to tap water and commercial chow (FR-2; Funabashi Farms, Chiba). All animals received humane care in compliance with the “Guiding Principles for the Care and Use of Laboratory Animals” formulated by The Japanese Pharmacological Society, and the protocol was approved by the Bioethical Committee of the Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd.

Benidipine (hydrochloride) was synthesized at Kyowa Hakko Kogyo (Tokyo). Diltiazem (hydrochloride) and AVP were purchased from Sigma (St. Louis, MO, USA). Benidipine and diltiazem were dissolved in physiological saline containing 0.1 vol% Tween 80 (Wako Pure Chemical, Osaka). Drug concentrations were adjusted to yield an injection volume of 0.1 mL/100 g of body weight. The doses of benidipine and diltiazem were selected based on the study by Karasawa et al. (2). AVP was diluted with physiological saline to a concentration of 1 IU/mL solution.

The antianginal effects of the drugs were assessed according to the method of Hirata et al. (7). Rats were anesthetized with sodium pentobarbital (60 mg/kg, i.p.).
Combination Therapy for Angina

The standard limb lead II electrocardiogram (ECG) was recorded to measure S-wave depression. The rats were allocated to the following 6 groups: vehicle (n = 12); benidipine, 3 μg/kg (n = 8); benidipine, 10 μg/kg (n = 8); diltiazem, 300 μg/kg (n = 8); diltiazem, 1000 μg/kg (n = 8); benidipine, 3 μg/kg + diltiazem, 300 μg/kg (n = 8). The test drugs were intravenously injected 5 min prior to the injection of AVP. AVP (1 IU/kg) was injected into the jugular vein, and ECG changes were recorded for the first 10 min following AVP injection. In a separate experiment, the effects of vehicle, benidipine at 3 μg/kg, diltiazem at 300 μg/kg, and their combination on blood pressure and heart rate were measured in normal anesthetized rats (each group consisted of 5 animals). The blood pressure was recorded on a polygraph through a blood pressure transducer connected to a cannula inserted into the carotid artery, and heart rate was measured by the blood pressure pulse wave. After each drug was intravenously administered, the changes of the blood pressure and heart rate were measured for 15 min.

All values are expressed as means ± S.E.M. All statistical calculations were performed using a computer and statistical analysis software (SAS, version 6.12; SAS Institute, Inc., Cary, NC, USA). Statistical analysis of the S-wave was performed using Student’s t- or the Aspin-Welch-test for comparison between two groups or using the Kruskal-Wallis test followed by the Steel’s test for multiple comparison. Intergroup comparisons of blood pressure and heart rate between the vehicle administration group and the test drug administration groups at each time point were made by nested variance analysis, and then significant differences were tested by Student’s t-test. A difference was considered to be statistically significant at P<0.05.

AVP is an antidiuretic hormone and a vasoconstrictor, where AVP produces vasoconstriction of small coronary arteries and increases total coronary resistance (8). The AVP-induced angina model is considered useful in evaluating antispasmodic effects of drugs in vivo (2, 7, 9 – 11). When AVP was injected in the rats, a depression of the S-wave in the lead II ECG appeared 10 min following AVP challenge (Fig. 1), suggesting subendocardial artery ischemia occlusion of a major artery, with collaterals from an uninvolved artery (12). Changes in ST-segment were used as an index of ischemic severity. According to the previous report (2), the fall of

![Fig. 1. Typical tracings of electrocardiogram (lead II) of anesthetized rats following intravenous injection of vasopressin.](image1)

**Fig. 1.** Typical tracings of electrocardiogram (lead II) of anesthetized rats following intravenous injection of vasopressin.

![Fig. 2. Effects of benidipine (1), diltiazem (2), and their combination (3) on the maximum changes in vasopressin-induced S-wave depression in the electrocardiogram (lead II) in anesthetized rats. Drugs were administered intravenously 5 min prior to the vasopressin injection. Columns are means ± S.E.M. of 8 – 12 rats. *P<0.05, **P<0.01, ***P<0.001 vs vehicle.](image2)

**Fig. 2.** Effects of benidipine (1), diltiazem (2), and their combination (3) on the maximum changes in vasopressin-induced S-wave depression in the electrocardiogram (lead II) in anesthetized rats. Drugs were administered intravenously 5 min prior to the vasopressin injection. Columns are means ± S.E.M. of 8 – 12 rats. *P<0.05, **P<0.01, ***P<0.001 vs vehicle.
S-wave was regarded as the fall of ST. Maximal S-wave depression was observed 4–5 min following AVP injection, consistent with previous reports (10, 11). Both benidipine (3 and 10 μg/kg) and diltiazem (300 and 1000 μg/kg) significantly inhibited the S-wave depression in a dose-dependent manner (Fig. 2). Co-administration of low doses of benidipine (3 μg/kg) and diltiazem (300 μg/kg) almost completely inhibited the S-wave depression, where the efficacy was similar to that obtained with the use of high doses of benidipine (10 μg/kg) or diltiazem (1000 μg/kg) (Fig. 2).

Both benidipine (3 μg/kg) and diltiazem (300 μg/kg) decreased or slightly decreased blood pressure in normal anesthetized rats (Fig. 3). Co-administration of benidipine (3 μg/kg) and diltiazem (300 μg/kg) decreased blood pressure to the level of the diltiazem (300 μg/kg) group. Diltiazem (300 μg/kg) and co-administration of benidipine (3 μg/kg) and diltiazem (300 μg/kg) tended to decrease heart rate, whereas benidipine (3 μg/kg) did not affect heart rate (Fig. 3).

In general, calcium channel blockers possess vaso-dilating and negative inotropic effects. Consequently, their antianginal effects can be related to their ability to increase coronary blood flow (i.e., increase in myocardial oxygen supply) and/or to reduce myocardial oxygen consumption. Although they share common mechanisms of action, they differ in their affinity for the various tissues in the cardiovascular system. Therefore, the observed differences in pharmacological properties are based on their chemical structures.

Benidipine, a 1,4-dihydropyridine, is highly selective for vascular tissue and has fewer effects on nodal tissue in the heart (13). Consequently, it is reasonable to assume that the antianginal effects of benidipine are essentially mediated by its antispasmodic effect or the increase in coronary oxygen supply resulting from increased coronary blood flow. Diltiazem, a representative benzothiazepine derivative, also increases coronary blood flow. However, when diltiazem was administered intravenously, the effect was transient and recovery was rapid (14). On the other hand, diltiazem had a negative inotropic effect and decreased the heart rate. Therefore, reduced coronary oxygen consumption may partly contribute to the antianginal effects of diltiazem.

In this study, the combined use of diltiazem and benidipine produced additive antianginal effects compared to the use of each drug alone. Myocardial ischemia is typified by an imbalance between the supply and demand of myocardial oxygen. The effects of the combined drug administration were probably due to the sum of the decrease in myocardial oxygen demand and the increase in oxygen supply. In this study, the combined use of benidipine and diltiazem did not significantly augment the hypotensive effects of each drug in normal anesthetized rats. Combined effects of benidipine at 3 μg/kg and diltiazem at 300 μg/kg on heart rate were comparable to those of diltiazem at 300 μg/kg, whereas the benidipine at 3 μg/kg had little effect on heart rate. Combination therapy of benidipine and diltiazem might possess favorable properties as a treatment for angina pectoris because benidipine has more potent coronary vasodilating activity than diltiazem, and diltiazem reduces myocardial oxygen demand more effectively than benidipine. The precise mechanism of the antianginal effects resulting from the...
combination strategy employed in the present study, however, remains unclear. In addition, it is important to examine the effects of the combination therapy in other animal models of myocardial ischemia (e.g., pacing-induced myocardial ischemia in the presence of significant coronary stenosis) in order to fully clarify the significance of this combination therapy in angina pectoris, and further investigations are necessary.

Diltiazem is widely used in the treatment of angina pectoris. However, its therapeutic utility has been limited by side effects such as bradycardia and atrioventricular (A-V) block (15). Quartaroli et al. demonstrated that diltiazem prolonged A-V conduction and caused bradycardia and A-V block at higher doses in dogs (14). In the present study, the co-administration of low doses of diltiazem (300 μg/kg) and benidipine (3 μg/kg) almost completely inhibited depression of the S-wave, where the efficacy was similar to that obtained with the use of high doses of diltiazem (1000 μg/kg) or benidipine (10 μg/kg). These results suggest that employment of a combination approach using low doses of diltiazem and benidipine can yield an antianginal effect equivalent to that observed with the use of higher doses of either drug alone, with fewer undesirable side effects.

In conclusion, the present results indicate that the combination of diltiazem and benidipine exerts potent antianginal effects in the vasopressin-induced angina rat model, suggesting that employment of such an administration strategy may be useful in the treatment of angina pectoris.

Acknowledgments

The excellent technical assistance of Ms. M. Kobayashi is greatly appreciated. We thank Drs. K. Nagashima and A. Karasawa for valuable discussion about this study. We are grateful to Drs. H. Miki and M. Nakamura for encouragement and support.

References